Pharmacokinetic evaluation of the digoxin-amiodarone interaction.
Amiodarone is known to raise serum digoxin levels. This study was designed to evaluate the pharmacokinetic basis of this interaction in 10 normal subjects. The pharmacokinetic variables for digoxin were determined after a 1.0 mg intravenous dose of digoxin in each subject, before and after oral amiodarone, 400 mg daily for 3 weeks. During amiodarone administration, systemic clearance of digoxin was reduced from 234 +/- 72 ml/min (mean +/- standard deviation) to 172 +/- 33 ml/min (p less than 0.01). This was due to reductions in both renal clearance (from 105 +/- 39 to 84 +/- 15 ml/min) (p less than 0.05) and nonrenal clearance (from 130 +/- 38 to 88 +/- 20 ml/min) (p less than 0.01). Digoxin half-life of elimination was prolonged from 34 +/- 13 to 40 +/- 16 hours (p less than 0.05). Digoxin volume of distribution was not significantly changed. Amiodarone caused a three- to fivefold increase in serum reverse triiodothyronine levels, but changes in thyroid function were not quantitatively related to the changes in digoxin pharmacokinetics. These alterations in digoxin pharmacokinetics produced by amiodarone explain the increase in serum digoxin level that has been observed when this drug combination has been used clinically.
D000328:Adult; D000638:Amiodarone / Q000378:metabolism* / Q000494:pharmacology; D001572:Benzofurans / Q000378:metabolism*; D003404:Creatinine / Q000378:metabolism; D004077:Digoxin / Q000378:metabolism* / Q000494:pharmacology; D004347:Drug Interactions; D006801:Humans; D007700:Kinetics; D008297:Male; D013960:Thyroid Function Tests; D014284:Triiodothyronine / Q000097:blood
D001572:Benzofurans; D014284:Triiodothyronine; D004077:Digoxin; D003404:Creatinine; D000638:Amiodarone